2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "LIBRETTO-432 Trial - Adjuvant Selpercatinib vs. Placebo in Stage IB-IIIA RET+ NSCLC"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Jonathan Goldman
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Jonathan Goldman
Login to view comments.
Click here to Login